文献速递中枢神经肿瘤放疗放疗物理与技术

微束放射治疗联合免疫检查点抑制剂在胶质瘤大鼠模型中的首次疗效评估

A first evaluation of the efficacy of minibeam radiation therapy combined with an immune check point inhibitor in a model of glioma-bearing rats.
PubMed 文献 · Clin Transl Radiat Oncol · 2025-01-06

本研究在胶质瘤大鼠模型中评估微束放射治疗(MBRT)联合免疫检查点抑制剂(ICI)的疗效。所有治疗组(ICI单用、常规放疗、常规放疗+ICI、MBRT、MBRT+ICI)均较未照射对照组延长生存。常规放疗30 Gy单次照射对正常组织毒性大,常规放疗+ICI似乎有毒;MBRT+ICI生存率优于ICI单用,但与常规放疗+ICI生存统计学等效,后者8只动物中6只肿瘤清除。

要点

  • MBRT+ICI生存率优于ICI单用。
  • 常规放疗30 Gy单次照射对正常组织高度有害。
  • 常规放疗+ICI似乎有毒,生存较常规放疗单用有降低趋势。

核心结论

  • 结果提示MBRT联合ICI具有一定优势,但需进一步研究确定最佳放疗-免疫联合方案及ICI注射与MBRT照射的时机。

研究设计与样本

  • 在胶质瘤大鼠模型中进行体内实验,比较MBRT、MBRT+ICI与常规放疗或ICI单用的生存获益。

主要发现

  • 所有治疗(ICI单用、常规放疗、常规放疗+ICI、MBRT、MBRT+ICI)均较未照射对照组延长生存。
  • 常规放疗单次30 Gy对正常组织高度有害,而MBRT无此表现。
  • 常规放疗+ICI似乎有毒。
  • MBRT+ICI生存率优于ICI单用。
  • 常规放疗+ICI组8只动物中6只肿瘤清除,但生存与MBRT+ICI统计学等效,且较常规放疗单用有生存降低趋势,提示该多模式治疗相关急性毒性。

局限性

  • 需进一步研究以确定最佳放疗-免疫联合方案及ICI注射与MBRT照射的时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Glioblastoma multiforme (GBM) continues to be a hopeless case today. Its treatment involves the use of multiple modalities. One of them is radiation therapy (RT), that is limited by normal tissue tolerances in GBM patients. GBM is widely recognized to induce local and systemic immunosuppression, which is a hindrance to the use of immune-modulating therapies. One possible strategy is to ally immunotherapy (IT) with novel RT approaches able to revert the immunosuppressive nature of GBM. One example is minibeam radiation therapy (MBRT). Preclinical experiments have shown that MBRT leads to a remarkable widening of the therapeutic window for GBM and elicits an effective immune priming. The main hypothesis of this study is that the activation of the immune system by MBRT would synergize with IT enhancing tumour control and minimizing toxicities. To validate it, in vivo experiments in a glioma rat model were performed. The goal was to assess the gain in survival of animals treated with MBRT, MBRT plus an immune check point inhibitor (ICI) versus conventional RT (CRT) or ICI alone. All treatments (ICI alone, CRT, CRT + ICI, MBRT and MBRT + ICI) increased survival with respect to the non-irradiated controls. However, the high radiation dose (30 Gy) delivered in one fraction in CRT is highly detrimental for normal tissues contrary to MBRT. The combination of CRT plus ICI appeared to be toxic. MBRT + ICI surpassed the survival rate with respect to ICI alone. When ICI was used with high-dose conventional irradiation, tumor eradication was observed in 6 out 8 animals. However, the survival was statistically equivalent to MBRT plus ICI, with a tendency to reduce survival in comparison with CRT alone, suggesting acute toxicity associated with this multimodal treatment. In conclusion, our results suggest some advantages for MBRT in combination with ICI. We need to conduct further work to determine the optimal RT-IT combination and schedule for ICI injection and MBRT irradiation.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Iturri L, Jouglar E, Gilbert C, et al. A first evaluation of the efficacy of minibeam radiation therapy combined with an immune check point inhibitor in a model of glioma-bearing rats. Clin Transl Radiat Oncol. 2025. PMID: 39898330. doi:10.1016/j.ctro.2025.100911

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。